IDEAYA Biosciences
NASDAQ · IDYA·South San Francisco, CA·Mid-cap·Phase 3
Clinical-stage precision oncology biotech developing synthetic lethality medicines. Lead asset darovasertib (PKC inhibitor) is in Phase 3 for primary uveal melanoma (neoadjuvant) and metastatic uveal melanoma. Pipeline includes IDE397 (MAT2A) and IDE161 (PARG).
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| IDEAYA Corporate Deck March 2026 | Corporate overview | March 9, 2026 | 27 |